-
Lorcaserin,
marketed under the
brand name Belviq, was a weight-loss drug
developed by
Arena Pharmaceuticals. It
reduces appetite by
activating a type of...
- derivatives, such as
Lorcaserin (Figure 6) have been
evaluated for
their potency and
selectivity for the 5-HT2C receptors.
Lorcaserin is a very
potent agonist...
- on the market,
Belviq (
lorcaserin), a weight-loss medication. The U.S. Food and Drug
Administration (FDA)
approved lorcaserin on June 27, 2012. The company...
- its
potential for
causing valvulopathies and
pulmonary hypertension)
Lorcaserin (withdrawn in the
United States by the FDA due to an
increased risk of...
-
Michele (May 8, 2013). "Schedules of
Controlled Substances:
Placement of
Lorcaserin Into
Schedule IV".
Federal Register. Drug
Enforcement Administration....
-
serotonin receptors in a
region of the
brain called the hypothalamus.
Lorcaserin (Belviq) was FDA
approved for
weight loss but was
withdrawn from the market...
- BI-4752, a
recently invented 5-HT2C
agonist that is even
superior to
lorcaserin. Womack, E. B.; Nelson, A. B. (1944). "Ethyl Diazoacetate".
Organic Syntheses...
- pFPP
Tryptamines Others AL-38022A
ALPHA Dimemebfe Efavirenz Glaucine Lorcaserin M-ALPHA RH-34 Also
empathogens in
general (e. g.: 5-APB, 5-MAPB, 6-APB...
- 2016,
exceeding that of the
dominant alternative obesity medications lorcaserin and phentermine/topiramate.
Despite being initially impeded by technical...
-
authorities rejected lorcaserin and phentermine-topiramate, in part
because of ****ociations of
heart valve problems with
lorcaserin and more
general heart...
